3 Questions: AIDS researchers on new vaccine results

September 29, 2009,
3 Questions: AIDS researchers on new vaccine results
Arup Chakraborty, MIT professor of chemical engineering, chemistry and biological engineering. Photo: Donna Coveney

(PhysOrg.com) -- On Thursday, an international research team reported that a new AIDS vaccine tested in more than 16,000 volunteers in Thailand protected a small but significant minority against infection. The new results mark the first time any vaccine has shown even partial success in clinical trials.

In this interview, Arup Chakraborty, MIT professor of chemical engineering, chemistry and biological engineering, and Bruce Walker, physician and investigator at Massachusetts General Hospital, share their thoughts on the new study.

Walker directs the Phillip T. and Susan M. Ragon Institute, a collaboration between MIT, Harvard and Massachusetts General Hospital launched earlier this year with a $100 million gift and the mission to develop an AIDS . Chakraborty is a team leader at the Institute.

Q: What is your reaction to the new study? How big a step forward is this in the search for an AIDS vaccine?

A: The data are clearly exciting because they are the first suggestion in humans that one might be able vaccinate people to lower the chance of getting infected with . The effect was very modest, so it is clear that this vaccine is not the answer, but it gives us important clues to follow to get to a vaccine with a stronger effect. These results also could end up not being significant - we don't yet know if the groups were matched for other possible confounding variables that affect transmission like HSV-2 infection and , which could influence the results.

Q: What challenges remain in the effort to develop an AIDS vaccine?

A: At the current time it is unclear what this vaccine did to provide weak protection, so it is unclear what needs to be boosted to make it better. Of 16,000 people in the trial, there were 70 infections in those that got a , and 51 in those that got a vaccine - not a huge benefit, but a signal nevertheless that the vaccine had some effect. The Ragon funding will allow us to move forward as quickly as possible to follow up on the clues from this trial.

Q: How does this advance affect the mission of the Ragon Institute, which was founded with the goal of developing an vaccine?

A: The data to us provide further support that an effective vaccine is possible. We have a long ways to go, but this is potentially a very important new clue to guide us.

Provided by Massachusetts Institute of Technology (news : web)

Related Stories

Recommended for you

HIV exports viral protein in cellular packages

February 15, 2018
HIV may be able to affect cells it can't directly infect by packaging a key protein within the host's cellular mail and sending it out into the body, according to a new study out of a University of North Carolina Lineberger ...

Can gene therapy be harnessed to fight the AIDS virus?

February 13, 2018
For more than a decade, the strongest AIDS drugs could not fully control Matt Chappell's HIV infection. Now his body controls it by itself, and researchers are trying to perfect the gene editing that made this possible.

Big data methods applied to the fitness landscape of the HIV envelope protein

February 7, 2018
Despite significant advances in medicine, there is still no effective vaccine for the human immunodeficiency virus (HIV), although recent hope has emerged through the discovery of antibodies capable of neutralizing diverse ...

Scientists report big improvements in HIV vaccine production

February 5, 2018
Research on HIV over the past decade has led to many promising ideas for vaccines to prevent infection by the AIDS virus, but very few candidate vaccines have been tested in clinical trials. One reason for this is the technical ...

Microbiome research refines HIV risk for women

January 25, 2018
Drawing from data collected for years by AIDS researchers in six African nations, scientists have pinpointed seven bacterial species whose presence in high concentrations may significantly increase the risk of HIV infection ...

Researchers find latent HIV reservoirs inherently resistant to elimination by CD8+ T-cells

January 22, 2018
The latest "kick-and-kill" research to eliminate the HIV virus uncovered a potential obstacle in finding a cure. A recent study by researchers at the George Washington University (GW) found that latent HIV reservoirs show ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.